Similar articles

• Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.

  FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, Brambilla R. FitzGerald JM, et al. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):427-35. doi: 10.1016/s0091-6749(99)70467-7. J Allergy Clin Immunol. 1999. PMID: 10069876 Clinical Trial.
• Addressing ethnic disparity in asthma trials.

  Radhakrishna N, Hew M. Radhakrishna N, et al. Respirology. 2014 Aug;19(6):775-6. doi: 10.1111/resp.12338. Epub 2014 Jun 26. Respirology. 2014. PMID: 24975919 No abstract available.
• Formoterol in the treatment of nocturnal asthma.

  Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Maesen FP, et al. Chest. 1990 Oct;98(4):866-70. doi: 10.1378/chest.98.4.866. Chest. 1990. PMID: 1976487 Clinical Trial.
• Formoterol delivered by Turbuhaler: in pediatric asthma.

  Cheer SM, Warner GT, Easthope SE. Cheer SM, et al. Paediatr Drugs. 2003;5(1):63-8; discussion 69. doi: 10.2165/00128072-200305010-00008. Paediatr Drugs. 2003. PMID: 12513109 Review.
• Inhaled budesonide/formoterol combination.

  McGavin JK, Goa KL, Jarvis B. McGavin JK, et al. Drugs. 2001;61(1):71-8; discussion 79-80. doi: 10.2165/00003495-200161010-00007. Drugs. 2001. PMID: 11217872 Review.